U.S. Continuous Renal Replacement Therapy Market To witness Huge Expansion By 2028

U.S. Continuous Renal Replacement Therapy Industry

The U.S. continuous renal replacement therapy (CRRT) market size is expected to reach USD 957.2 million by 2028, according to a new report by Grand View Research, Inc. The market is projected to expand at a compound annual growth rate (CAGR) of 6.1% from 2021 to 2028. The anticipated growth in the U.S. market can be attributed to the rising number of ICU patients suffering from Acute Kidney Injury (AKI) and the increasing incidence of sepsis. Additionally, the COVID-19 pandemic has positively impacted the market, further driving its growth. The presence of well-established key players in the country, who are focused on developing and commercializing technologically advanced devices, along with government initiatives to raise awareness about CRRT, are also expected to support market expansion during the forecast period.

The growing prevalence of fluid overload, a condition that often affects AKI patients in critical care settings, is a major factor boosting the demand for CRRT devices. Moreover, the U.S. Food and Drug Administration (FDA) has implemented stringent regulations on manufacturers to ensure the availability of high-quality CRRT devices in intensive care units (ICUs), which is likely to create lucrative growth opportunities for the market in the near future.

Key market players, including Baxter International, Inc.; Fresenius Kabi; and Medtronic, are heavily investing in research and development efforts to introduce technologically advanced CRRT devices. For instance, Baxter has developed the PRISMAFLEX critical care system, a versatile platform that allows personalized therapy tailored to a patient’s specific needs and comfort. Similarly, B. Braun’s Diapact CRRT system is equipped with advanced technology designed for the effective treatment of AKI and kidney disorders, enabling critical blood filtering processes to be conducted accurately and without hindering patient recovery. These innovations in CRRT systems, combined with ongoing technological advancements, are expected to drive the increased adoption of CRRT devices, thereby boosting the U.S. market growth in the coming years.

Curious about the U.S. Continuous Renal Replacement Therapy Market, Download your FREE sample copy now and get a sneak peek into the latest insights and trends.

U.S. Continuous Renal Replacement Therapy Market Segments Highlights:

• In terms of product, the liquids segment dominated the market in terms of revenue in 2020. The growing number of manufacturers supplying dialysate and replacement fluids for RRT is contributing to the segment growth
• The disposables product segment is projected to expand significantly during the forecast period owing to the increasing use of hemofilter, fluids, charcoal filters, and other consumables in CRRT treatments
• By modality, in 2020, the Continuous Venovenous Hemodialysis (CVVHD) segment dominated the market in terms of a number of procedures/treatments. The Continuous Venovenous Hemodiafiltration (CVVHDF) segment is expected to expand at the highest volume-based CAGR during the forecast period

U.S. Continuous Renal Replacement Therapy Market Report Segmentation

Grand View Research has segmented the U.S. continuous renal replacement therapy market on the basis of product and modality:

U.S. Continuous Renal Replacement Therapy Product Outlook (Revenue, USD Million, 2016 - 2028)

• CRRT System
• Disposables
• Liquids

U.S. Continuous Renal Replacement Therapy Modality Outlook (Revenue, USD Million, 2016 - 2028)

• Slow Continuous Ultrafiltration (SCUF)
• Continuous Venovenous Hemofiltration (CVVH)
• Continuous Venovenous Hemodialysis (CVVHD)
• Continuous Venovenous Hemodiafiltration (CVVHDF)

Key U.S. Continuous Renal Replacement Therapy Company Insights

• Baxter
• Braun Melsungen AG
• Fresenius Medical Care AG
• Medtronic
• Asahi Kasei Medical Co., Ltd.
• Nipro Corporation

Order a free sample PDF of the U.S. Continuous Renal Replacement Therapy Market Intelligence Study, published by Grand View Research.